Ipilimumab/nivolumab/pembrolizumabNeuromuscular disorders/pneumonitis: 3 case reports

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2021年 / 1851卷 / 1期

关键词：

D O I：

10.1007/s40278-021-94285-1

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：195 / 195

相关论文

共 50 条

[1] Ipilimumab/nivolumab/pembrolizumabImmune-related colitis, pneumonitis and thyroiditis: 3 case reports
Reactions Weekly, 2023, 1948 (1) : 246 - 246
[2] Ipilimumab/nivolumab/pembrolizumabThyroid disorders: 4 case reports
Reactions Weekly, 2022, 1902 (1) : 256 - 256
[3] Ipilimumab/nivolumab/pembrolizumabLymphadenopathy, pneumonitis, myocarditis and hyperthyroidism: 7 case reports
Reactions Weekly, 2018, 1693 (1) : 279 - 279
[4] Ipilimumab/nivolumab/vemurafenibUveitis: 3 case reports
Reactions Weekly, 2016, 1606 (1) : 93 - 93
[5] Ipilimumab/nivolumabOesophagitis and pneumonitis: 3 case reports
Reactions Weekly, 2021, 1866 (1) : 226 - 226
[6] Ipilimumab/Nivolumab/PembrolizumabHypophysitis: 3 case reports
Reactions Weekly, 2024, 2037 (1) : 222 - 222
[7] Ipilimumab/nivolumab/pembrolizumabGastroparesis: 3 case reports
Reactions Weekly, 2021, 1871 (1) : 216 - 216
[8] Ipilimumab/nivolumab/pembrolizumabMyocarditis: 3 case reports
Reactions Weekly, 2022, 1909 (1) : 303 - 303
[9] Ipilimumab/nivolumab/pembrolizumabThyroiditis: 3 case reports
Reactions Weekly, 2019, 1748 (1) : 268 - 268
[10] Ipilimumab/nivolumab/pembrolizumabSarcoidosis: 3 case reports
Reactions Weekly, 2017, 1678 (1) : 109 - 109

← 1 2 3 4 5 →